ORANGE 18.325 € (-1,61 %) 
ADYEN 943.000 € (-1,39 %) UBISOFT ENTERTAIN 4.678 € (-2,28 %) 
DSM FIRMENICH AG 71.320 € (+5,32 %) MICHELIN 31.200 € (+0,22 %) UMG 20.450 € (+1,19 %) 
AEGON 7.416 € (+0,76 %) HAVAS 16.100 € (-1,23 %) COVIVIO HOTELS 22.500 € (+0,90 %) WOLTERS KLUWER 63.020 € (-0,88 %) NANOBIOTIX 33.520 € (-9,26 %) ESSILORLUXOTTICA 175.400 € (-0,74 %) VALEO 12.345 € (+0,78 %) FORVIA 10.060 € (-0,54 %) TOTALENERGIES 80.260 € (+0,82 %) PUBLICIS GROUPE SA 83.400 € (+0,05 %) DASSAULT SYSTEMES 19.985 € (-1,26 %) EURAZEO 45.140 € (-0,49 %) KPN KON 4.619 € (-1,13 %) KALRAY 9.690 € (+9,12 %) ELIOR GROUP 2.064 € (-26,76 %) ENGIE 27.200 € (-0,48 %) TONNER DRONES 0.040 € (+2,83 %) EBUSCO HOLDING 0.300 € (0,00 %) PARROT 11.060 € (+12,28 %) EUTELSAT COMMUNIC. 3.833 € (+22,46 %) KLEPIERRE 34.800 € (+0,46 %) BAM GROEP KON 8.945 € (+2,64 %) TKH GROUP 46.340 € (+0,52 %) IPSEN 160.600 € (+0,63 %) GECINA 72.700 € (+0,48 %) EXOSENS 64.000 € (+4,23 %) HEIJMANS KON 93.150 € (+7,32 %) SOITEC 166.600 € (+5,44 %) DASSAULT AVIATION 286.000 € (+0,56 %) 
RELX 28.600 € (-0,63 %) ASR NEDERLAND 67.120 € (+1,08 %) SOCIETE GENERALE 68.400 € (-1,48 %) ING GROEP N.V. 26.145 € (+0,69 %) PATRIMOINE ET COMM 23.700 € (0,00 %) ALFEN 15.950 € (+25,00 %) SHELL PLC 37.455 € (+0,50 %) ABIVAX 105.100 € (+2,14 %) ADP 108.400 € (-2,17 %) STMICROELECTRONICS 55.080 € (-0,34 %) TOOSLA 0.013 € (+1,59 %) AIR LIQUIDE 179.720 € (+1,53 %) DANONE 62.860 € (-1,01 %) BNP PARIBAS ACT.A 89.160 € (-0,13 %) SAFRAN 279.700 € (-0,99 %) SANOFI 77.540 € (+1,13 %) L'OREAL 359.450 € (-0,21 %) LVMH 473.550 € (-0,05 %) VOYAGEURS DU MONDE 144.500 € (-0,69 %) AIR FRANCE -KLM 10.090 € (-0,98 %) AMUNDI 85.800 € (-0,29 %) FLORENTAISE 0.600 € (0,00 %) FONCIERE INEA 35.600 € (0,00 %) ATOS 40.740 € (+0,84 %) EURONEXT 150.200 € (+1,76 %) |
21/05/2026 22:00
Inventiva to Present at 2026 Jefferies Global Healthcare ConferenceInventiva to Present at 2026 Jefferies Global Healthcare ConferenceDaix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. Presentation details are as follows: Date: Wednesday, June 3, 2026 About InventivaInventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts
Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière